Influenza A Viral Infections Drug Development Pipeline Review, 2018

This report provides an overview of the pipeline landscape for influenza A viral infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for influenza A H3N2, H1N1, H5N1 and H7N9 subtype infections, and features dormant and discontinued products.

Influenza is an acute infection of the respiratory tract that predominately affects the nose, throat and bronchi, and less commonly the lungs. Influenza viruses have a single-stranded segmented RNA genome. They belong to the family Orthomyxoviridae, and are categorized into three genera based on their core proteins – A, B and C. Influenza A and B viruses are responsible for the majority of symptomatic cases of influenza in humans.

Influenza A viruses can be further categorized based on their expression of two viral surface proteins: hemagglutinin (H); and neuraminidase (N). These viruses are known to have high mutation rates, with frequent changes to the viral protein structure.

Scope

– Which companies are the most active within the pipeline for influenza A viral infections?

– Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?

– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

– What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Companies mentioned

AbbVie Inc

Adimmune Corp

Akshaya Bio Inc

Altimmune Inc

Antigen Express Inc

Aphios Corp

AusBio Ltd

Beijing Minhai Biotechnology Co Ltd

BioCryst Pharmaceuticals Inc

BiondVax Pharmaceuticals Ltd

Cadila Healthcare Ltd

Celltrion Inc

CEL-SCI Corp

Cilian AG

Cocrystal Pharma Inc

ContraFect Corp

Curevac AG

Emergent BioSolutions Inc

EpiVax Inc

Etubics Corp

FluGen Inc

Gemmus Pharma Inc

Genentech Inc

GlaxoSmithKline Plc

Hemispherx Biopharma Inc

iBio Inc

Influenza A Virus, H1N1 Subtype Infections

Influenza A Virus, H3N2 Subtype Infections

Influenza A Virus, H5N1 Subtype Infections

Influenza A Virus, H7N9 Subtype Infections

Inovio Pharmaceuticals Inc

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Karyopharm Therapeutics Inc

Kineta Inc

Kyowa Hakko Kirin Co Ltd

Lakewood-Amedex Inc

Medicago Inc

Medigen Vaccine Biologics Corp

MedImmune LLC

Microbiotix Inc

Moderna Therapeutics Inc

Mucosis BV (Inactive)

NanoBio Corp

NanoViricides Inc

Novavax Inc

Ology Bioservices Inc

OPKO Health Inc

PaxVax Inc

PeptiDream Inc

Recce Ltd

Sanofi

Sanofi Pasteur SA

Sarepta Therapeutics Inc

Shionogi & Co Ltd

SK Chemicals Co Ltd

TechnoVax Inc

Touchlight Genetics Ltd

Vaccibody AS

Vaxart Inc

Vaxine Pty Ltd

VBI Vaccines Inc

VirionHealth Ltd

Visterra Inc

Vivaldi Biosciences Inc

Table of Contents

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 8

2 Introduction 10

2.1 Influenza A Viral Infections Report Coverage 10

2.2 Influenza A Virus, H3N2 Subtype Infections – Overview 10

2.3 Influenza A Virus, H1N1 Subtype Infections – Overview 10

2.4 Influenza A Virus, H5N1 Subtype Infections – Overview 10

2.5 Influenza A Virus, H7N9 Subtype Infections – Overview 10

3 Therapeutics Development 11

3.1 Influenza A Virus, H3N2 Subtype Infections 11

3.2 Influenza A Virus, H1N1 Subtype Infections 19

3.3 Influenza A Virus, H5N1 Subtype Infections 31

3.4 Influenza A Virus, H7N9 Subtype Infections 41

4 Therapeutics Assessment 48

4.1 Influenza A Virus, H3N2 Subtype Infections 48

4.2 Influenza A Virus, H1N1 Subtype Infections 55

4.3 Influenza A Virus, H5N1 Subtype Infections 62

4.4 Influenza A Virus, H7N9 Subtype Infections 69

5 Companies Involved in Therapeutics Development 75

5.1 Influenza A Virus, H3N2 Subtype Infections 75

5.2 Influenza A Virus, H1N1 Subtype Infections 89

5.3 Influenza A Virus, H5N1 Subtype Infections 114

5.4 Influenza A Virus, H7N9 Subtype Infections 130

6 Dormant Projects 140

6.1 Influenza A Virus, H3N2 Subtype Infections 140

6.2 Influenza A Virus, H1N1 Subtype Infections 142

6.3 Influenza A Virus, H5N1 Subtype Infections 146

6.4 Influenza A Virus, H7N9 Subtype Infections 151

7 Discontinued Products 152

7.1 Influenza A Virus, H3N2 Subtype Infections 152

7.2 Influenza A Virus, H1N1 Subtype Infections 153

7.3 Influenza A Virus, H5N1 Subtype Infections 153

8 Product Development Milestones 154

8.1 Influenza A Virus, H3N2 Subtype Infections 154

8.2 Influenza A Virus, H1N1 Subtype Infections 160

8.3 Influenza A Virus, H5N1 Subtype Infections 174

8.4 Influenza A Virus, H7N9 Subtype Infections 185

9 Appendix 187

9.1 Methodology 187

9.2 Coverage 187

9.3 Secondary Research 187

9.4 Primary Research 187

9.5 Expert Panel Validation 187

9.6 Contact Us 188

9.7 Disclaimer 188

List of Tables

1.1 List of Tables

Table 1: Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections 11

Table 2: Number of Products under Development by Companies Influenza A Virus, H3N2 Subtype Infections 12

Table 3: Number of Products under Development by Universities/Institutes Influenza A Virus, H3N2 Subtype Infections 14

Table 4: Products under Development by Companies Influenza A Virus, H3N2 Subtype Infections 15

Table 5: Products under Development by Universities/Institutes Influenza A Virus, H3N2 Subtype Infections 18

Table 6: Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections 19

Table 7: Number of Products under Development by Companies, Influenza A Virus, H1N1 Subtype Infections 21

Table 8: Number of Products under Development by Universities/Institutes, Influenza A Virus, H1N1 Subtype Infections 23

Table 9: Products under Development by Companies, Influenza A Virus, H1N1 Subtype Infections 24

Table 10: Products under Development by Universities/Institutes, Influenza A Virus, H1N1 Subtype Infections 30

Table 11: Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections 32

Table 12: Number of Products under Development by Companies, Influenza A Virus, H5N1 Subtype Infections 34

Table 13: Number of Products under Development by Universities/Institutes, Influenza A Virus, H5N1 Subtype Infections 36

Table 14: Products under Development by Companies, Influenza A Virus, H5N1 Subtype Infections 37

Table 15: Products under Development by Universities/Institutes, Influenza A Virus, H5N1 Subtype Infections 40

Table 16: Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections 41

Table 17: Number of Products under Development by Companies, Influenza A Virus, H7N9 Subtype Infections 43

Table 18: Number of Products under Development by Universities/Institutes, Influenza A Virus, H7N9 Subtype Infections 44

Table 19: Products under Development by Companies, Influenza A Virus, H7N9 Subtype Infections 45

Table 20: Products under Development by Universities/Institutes, Influenza A Virus, H7N9 Subtype Infections 47

Table 21: Number of Products by Stage and Target, Influenza A Virus, H3N2 Subtype Infections 49

Table 22: Number of Products by Stage and Mechanism of Action, Influenza A Virus, H3N2 Subtype Infections 51

Table 23: Number of Products by Stage and Route of Administration, Influenza A Virus, H3N2 Subtype Infections 53

Table 24: Number of Products by Stage and Molecule Type, Influenza A Virus, H3N2 Subtype Infections 55

Table 25: Number of Products by Stage and Target, Influenza A Virus, H3N2 Subtype Infections 56

Table 26: Number of Products by Stage and Mechanism of Action, Influenza A Virus, H3N2 Subtype Infections 58

Table 27: Number of Products by Stage and Route of Administration, Influenza A Virus, H3N2 Subtype Infections 60

Table 28: Number of Products by Stage and Molecule Type, Influenza A Virus, H3N2 Subtype Infections 62

Table 29: Number of Products by Stage and Target, Influenza A Virus, H5N1 Subtype Infections 63

Table 30: Number of Products by Stage and Mechanism of Action, Influenza A Virus, H5N1 Subtype Infections 65

Table 31: Number of Products by Stage and Route of Administration, Influenza A Virus, H5N1 Subtype Infections 67

Table 32: Number of Products by Stage and Molecule Type, Influenza A Virus, H5N1 Subtype Infections 68

Table 33: Number of Products by Stage and Target, Influenza A Virus, H7N9 Subtype Infections 70

Table 34: Number of Products by Stage and Mechanism of Action, Influenza A Virus, H7N9 Subtype Infections 71

Table 35: Number of Products by Stage and Route of Administration, Influenza A Virus, H7N9 Subtype Infections 73

Table 36: Number of Products by Stage and Molecule Type, Influenza A Virus, H7N9 Subtype Infections 74

Table 37: Influenza A Virus, H3N2 Subtype Infections – Pipeline by AbbVie Inc 75

Table 38: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Adimmune Corp 76

Table 39: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Aphios Corp 76

Table 40: Influenza A Virus, H3N2 Subtype Infections – Pipeline by AusBio Ltd 77

Table 41: Influenza A Virus, H3N2 Subtype Infections – Pipeline by BioCryst Pharmaceuticals Inc 77

Table 42: Influenza A Virus, H3N2 Subtype Infections – Pipeline by BiondVax Pharmaceuticals Ltd 78

Table 43: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Cadila Healthcare Ltd 78

Table 44: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Celltrion Inc 79

Table 45: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Emergent BioSolutions Inc 80

Table 46: Influenza A Virus, H3N2 Subtype Infections – Pipeline by FluGen Inc 80

Table 47: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Inovio Pharmaceuticals Inc 81

Table 48: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd 81

Table 49: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Johnson & Johnson 82

Table 50: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Medicago Inc 83

Table 51: Influenza A Virus, H3N2 Subtype Infections – Pipeline by MedImmune LLC 83

Table 52: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Mucosis BV (Inactive) 84

Table 53: Influenza A Virus, H3N2 Subtype Infections – Pipeline by NanoViricides Inc 84

Table 54: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Novavax Inc 85

Table 55: Influenza A Virus, H3N2 Subtype Infections – Pipeline by OPKO Health Inc 85

Table 56: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Sanofi 86

Table 57: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Sanofi Pasteur SA 87

Table 58: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Sarepta Therapeutics Inc 87

Table 59: Influenza A Virus, H3N2 Subtype Infections – Pipeline by SK Chemicals Co Ltd 88

Table 60: Influenza A Virus, H3N2 Subtype Infections – Pipeline by VBI Vaccines Inc 88

Table 61: Influenza A Virus, H1N1 Subtype Infections – Pipeline by AbbVie Inc 89

List of Figures

1.2 List of Figures

Figure 1: Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections 11

Figure 2: Number of Products under Development by Companies, Influenza A Virus, H3N2 Subtype Infections 12

Figure 3: Number of Products under Development by Universities/Institutes Influenza A Virus, H3N2 Subtype Infections 14

Figure 4: Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections 19

Figure 5: Number of Products under Development by Companies, Influenza A Virus, H1N1 Subtype Infections 20

Figure 6: Number of Products under Development by Universities/Institutes, Influenza A Virus, H1N1 Subtype Infections 23

Figure 7: Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections 31

Figure 8: Number of Products under Development by Companies, Influenza A Virus, H5N1 Subtype Infections 33

Figure 9: Number of Products under Development by Universities/Institutes, Influenza A Virus, H5N1 Subtype Infections 36

Figure 10: Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections 41

Figure 11: Number of Products under Development by Companies, Influenza A Virus, H7N9 Subtype Infections 42

Figure 12: Number of Products under Development by Universities/Institutes, Influenza A Virus, H7N9 Subtype Infections 44

Figure 13: Number of Products by Top 10 Targets, Influenza A Virus, H3N2 Subtype Infections 48

Figure 14: Number of Products by Stage and Top 10 Targets, Influenza A Virus, H3N2 Subtype Infections 48

Figure 15: Number of Products by Top 10 Mechanism of Actions, Influenza A Virus, H3N2 Subtype Infections 50

Figure 16: Number of Products by Stage and Top 10 Mechanism of Actions, Influenza A Virus, H3N2 Subtype Infections 50

Figure 17: Number of Products by Routes of Administration, Influenza A Virus, H3N2 Subtype Infections 52

Figure 18: Number of Products by Stage and Routes of Administration, Influenza A Virus, H3N2 Subtype Infections 52

Figure 19: Number of Products by Top 10 Molecule Types, Influenza A Virus, H3N2 Subtype Infections 54

Figure 20: Number of Products by Stage and Top 10 Molecule Types, Influenza A Virus, H3N2 Subtype Infections 54

Figure 21: Number of Products by Top 10 Targets, Influenza A Virus, H3N2 Subtype Infections 55

Figure 22: Number of Products by Stage and Top 10 Targets, Influenza A Virus, H3N2 Subtype Infections 56

Figure 23: Number of Products by Top 10 Mechanism of Actions, Influenza A Virus, H3N2 Subtype Infections 57

Figure 24: Number of Products by Stage and Top 10 Mechanism of Actions, Influenza A Virus, H3N2 Subtype Infections 57

Figure 25: Number of Products by Top 10 Routes of Administration, Influenza A Virus, H3N2 Subtype Infections 59

Figure 26: Number of Products by Stage and Top 10 Routes of Administration, Influenza A Virus, H3N2 Subtype Infections 59

Figure 27: Number of Products by Top 10 Molecule Types, Influenza A Virus, H3N2 Subtype Infections 61

Figure 28: Number of Products by Stage and Top 10 Molecule Types, Influenza A Virus, H3N2 Subtype Infections 61

Figure 29: Number of Products by Top 10 Targets, Influenza A Virus, H5N1 Subtype Infections 62

Figure 30: Number of Products by Stage and Top 10 Targets, Influenza A Virus, H5N1 Subtype Infections 63

Figure 31: Number of Products by Top 10 Mechanism of Actions, Influenza A Virus, H5N1 Subtype Infections 64

Figure 32: Number of Products by Stage and Top 10 Mechanism of Actions, Influenza A Virus, H5N1 Subtype Infections 64

Figure 33: Number of Products by Routes of Administration, Influenza A Virus, H5N1 Subtype Infections 66

Figure 34: Number of Products by Stage and Routes of Administration, Influenza A Virus, H5N1 Subtype Infections 66

Figure 35: Number of Products by Top 10 Molecule Types, Influenza A Virus, H5N1 Subtype Infections 67

Figure 36: Number of Products by Stage and Top 10 Molecule Types, Influenza A Virus, H5N1 Subtype Infections 68

Figure 37: Number of Products by Targets, Influenza A Virus, H7N9 Subtype Infections 69

Figure 38: Number of Products by Stage and Targets, Influenza A Virus, H7N9 Subtype Infections 69

Figure 39: Number of Products by Mechanism of Actions, Influenza A Virus, H7N9 Subtype Infections 70

Figure 40: Number of Products by Stage and Mechanism of Actions, Influenza A Virus, H7N9 Subtype Infections 71

Figure 41: Number of Products by Routes of Administration, Influenza A Virus, H7N9 Subtype Infections 72

Figure 42: Number of Products by Stage and Routes of Administration, Influenza A Virus, H7N9 Subtype Infections 72

Figure 43: Number of Products by Molecule Types, Influenza A Virus, H7N9 Subtype Infections 73

Figure 44: Number of Products by Stage and Molecule Types, Influenza A Virus, H7N9 Subtype Infections 74

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports